Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dolutegravir/Rilpivirine FDC vs Separate Tablets
NCT02741557Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir + rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Area under the concentration-time curve from time 0 extrapolated to infinity, Area under the concentration-time curve from time 0 to the last measurable timepoint and 1 more. Started May 2016; status: completed.
02
Drugs
dolutegravir + rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02741557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741557.